scholarly journals Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models

2018 ◽  
Author(s):  
Ronald Lubet ◽  
Vernon Steele ◽  
M. Juliana ◽  
Ann Bode ◽  
Fariba Moeinpour ◽  
...  
Keyword(s):  
Mammary Cancer ◽  
Egfr Inhibitors ◽  
Akt Inhibitor ◽  
Cancer Models

scholarly journals [Corrigendum] Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor�MK2206 in mammary cancer models

2018 ◽  
Author(s):  
Ronald Lubet ◽  
Vernon Steele ◽  
M. Juliana ◽  
Ann Bode ◽  
Fariba Moeinpour ◽  
...  
Keyword(s):  
Mammary Cancer ◽  
Egfr Inhibitors ◽  
Akt Inhibitor ◽  
Cancer Models

Antitumour activity of coumarin in prostate and mammary cancer models

1994 ◽  
Vol 120 (S1) ◽  
pp. S14-S16 ◽  
Author(s):  
E. von Angerer ◽  
M. Kager ◽  
A. Maucher
Keyword(s):  
Mammary Cancer ◽  
Antitumour Activity ◽  
Cancer Models

scholarly journals Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models

2015 ◽  
Vol 47 (2) ◽  
pp. 446-454 ◽  
Author(s):  
CLAIRE CRAFTER ◽  
JOHN P. VINCENT ◽  
ERIC TANG ◽  
PHILLIPPA DUDLEY ◽  
NEIL H. JAMES ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Akt Inhibitor ◽  
Cancer Models

Comparing Genetically Engineered Mouse Mammary Cancer Models with Human Breast Cancer by Expression Profiling1

2007 ◽  
Vol 28 (1) ◽  
pp. 39-51 ◽  
Author(s):  
Alexander N. Shoushtari ◽  
Aleksandra M. Michalowska ◽  
Jeffrey E. Green
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
Mammary Cancer ◽  
Genetically Engineered ◽  
Human Breast ◽  
Cancer Models
Sign in / Sign up

Export Citation Format

Share Document